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Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) has been used as a rapid method
for the detection of human genetic polymorphisms. In particular, the mutations in the human HEXA gene that
cause the infantile Tay–Sachs disease have been studied using MALDI-MS to demonstrate the feasibility of this
technique for use in clinical and diagnostic analysis. The protocols involved in this approach include,
polymerase chain reaction for the amplification of the mutation site from buccal cell DNA, followed by
restriction enzyme digestion of the amplified regions of the template cells. The products of amplification and
digestion were studied using MALDI-MS. MALDI-MS experiments are shown to provide essentially the same
information as obtained from gel electrophoresis but orders of magnitude faster. © 1997 by John Wiley & Sons,
Ltd.
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The identification of genes and specific mutations
associated with different genetic disorders is an impor-
tant problem in clinical diagnosis. One such genetic
disorder that has received much attention is Tay–Sachs
disease (TSD). This genetically inherited disorder has a
relatively high incidence in specific populations, in
particular, in the descendants of Ashkenazi Jews1,2 and
French-Canadians.3 It is an autosomal recessive lysoso-
mal-storage disorder that results from a deficiency of
the α-subunit of hexosaminase A (HEXA). In the
absence of this enzyme, unhydrolyzed GM2 ganglioside
accumulates in the neuronal tissues resulting in pro-
gressive neurologic degeneration. For infants who are
homozygous recessive for Tay–Sachs alleles, death
usually occurs by the age of three.
Voluntary screening programs based on biochemical
assays for Tay–Sachs heterozygous carriers are availa-
ble. These tests measure the HEXA activity in the
serum and tissues of patients. However, results from
such tests are not accurate due to many factors that
could result in an increase4,5 or a decrease6 in the
apparent percentage of HEXA activity, thus making it
an unreliable indicator of the carrier state. Also the
presence of benign or ‘variant’ mutations can cause
HEXA enzyme deficiency, giving rise to false positive
results in the enzyme assays. An alternative to the
enzyme analysis that is more specific, is a DNA-based
screening test for carriers of TSD. This involves
methods to identify the specific mutation in the HEXA
gene of patients. Many different mutations have been
identified in the HEXA gene, but three are responsible
for most of the mutations in the Ashkenazi Jewish
population. Studies have shown that 70% of the
patients have a four base-pair insertion mutation in
exon 11.7 A splice-junction mutation at the 5' end of
intron 12 of the gene, which was the first identified
mutation, accounts for 20–30% of the cases of infantile
TSD.8 The last major mutation identified to date that is
responsible for adult onset GM2 gangliosidosis, involves
a G to A nucleotide substitution in exon 7 and is a rare
mutation, found only in 3% of the patient
population.9
The presence or absence of a mutation site in DNA
analysis can be confirmed by the combination of
polymerase chain reaction (PCR) and restriction length
fragment polymorphism (RFLP). The amplification of
small regions of the gene for detection of polymorphic
sites has been made possible by the introduction of
PCR.10 The amplified DNA can be detected by various
methods11–13 most commonly, gel electrophoresis. In
addition, the presence of a mutation can be recognized
using RFLP if a mutation occurs at a restriction site or
results in a change in distance between two restriction
sites.
The most common detection method used to study
PCR products and their restriction enzyme digests is
gel electrophoresis. The main drawback of the gel
electrophoretic method is the time required for separa-
tion of the amplified and digested products. Another
disadvantage of the gel method is that detection of low
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Table 1. Primer sequence and PCR amplification conditions
Amplifying gene Primers’ sequence Denaturation Annealing Extension Final extension # of cycles Final product
Tay–Sachs 5 – AGA TTC 94 °C for 1 min 58 °C for 1 min 72 °C for 1 min 72 °C for 10 min 35 195
Exon 11 AGC CAG ACA 199
CAA TCA T




Tay–Sachs 5 – TCT AAG 94 °C for 1 min 59 °C for 1 min 72 °C for 1 min 72 °C for 10 min 35 120





Table 2. Restriction endonuclease digestion of PCR
amplified Tay–Sachs genes
PCR product Restriction Fragment length bp Recognition Incubation
enzyme sequence conditions
Tay–Sachs Hae III 84,56,43,12normal 5’-GG/CC-3’ 37 °C 
Exon II 84,56,47,43,12mut for 4 h
Tay–Sachs Dde I 100,20normal 5’-C/T(G,A)AG,-3’ 37 °C
Intron 12 64,36,20mut for 4 h
molecular weight products ( ≤ 40 bp, for example, from
restriction enzymatic digestion) is difficult without the
incorporation of radioactive labeling. With the routine
ethidium bromide staining method for DNA detection
by gel electrophoresis, low molecular weight samples
have reduced number of intercalation sites for the dye.
As a result, the bands on the gel are not easily detected.
New rapid methods are required that can quickly
provide the same information obtained from the gel
methods.
A technique capable of rapid analysis is MALDI-MS.
Matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry was originally introduced in 1988 by
Karas and Hillenkamp14 for analyzing proteins.
MALDI typically uses a small matrix molecule that
absorbs photons of a given energy to eject labile
molecules into the gas phase intact or with minimum
fragmentation. Since its introduction, this method has
undergone a number of modifications to accommodate
analyses of molecules as complex as DNA. Oligonu-
cleotides up to 100 bases long were detected using
MALDI after the advent of 3-hydroxypicolinic acid
(3-HPA) as a DNA specific matrix.15 Using 3-HPA,
alone or in combination with picolinic acid (PA),
detection of double stranded DNA up to 622 bp in
complicated digest mixtures has been reported from
this lab.16 Chen and co-workers used 3-HPA to detect
DNA of 500 bp in length produced via PCR.17 Other
developments in MALDI analysis of DNA include on-
probe18 and off-probe19–21 purification procedures to
reduce adduct formation from K+ , Na+ and Fe2+
cations. The use of nafion and nitrocellulose mem-
branes as active substrates improves MALDI-MS
detection of DNA in terms of reproducibility and
sensitivity as shown by Liu et al.22 Further, improve-
ments to mass spectral resolution using pulsed delayed
extraction methods23–25 have become the recent focus
of many labs.
In this report we demonstrate the feasibility of
Figure 1. Sequence of the amplified Exon 11 region of the Tay–Sachs gene showing the 4 bp polymorphic site.
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MALDI-MS in combination with on-probe purification
by nitrocellulose membranes as a cost-effective and
rapid technique to detect human genetic variants for
Tay–Sachs disease. Both the four base-pair insertion
mutation in the exon 11 of the α-chain of the Tay–Sachs
gene as well as the splice-junction mutation at the 5'
end of the intron 12 were studied. Samples from various
donors, taken using the buccal cell sample method were
amplified and enzymatically digested followed by
MALDI-MS analysis. The mass spectral results
obtained were compared with the corresponding data
from gel electrophoresis demonstrating the capabilities
of the MALDI technique for clinical diagnosis. We have
thus demonstrated the use of MALDI-MS to detect
both low and high molecular weight products with high
sensitivity and accuracy.
EXPERIMENTAL
Extraction of DNA from buccal cells
The use of buccal cell DNA from the inner cheek for
PCR amplification has been reported earlier22 and will
be briefly discussed here. For our experiments, buccal
epithelial cells were extracted by twirling a sterile
cytology brush for 30 seconds on the inner cheek of the
mouth. The DNA was then extracted by lysing the cells
with 400 µL of 50 mM NaOH in a microcentrifuge tube.
After heating the mixture at 95 °C for 5 min, the DNA
solution was neutralized by adding 40 µL of 1M Tris and
the stock solution was stored at 4 °C for further use in
PCR analysis.
An alternative method of extracting DNA from
buccal cells was also used. In this procedure we used
the purification kit provided by Gentra Systems (Pure-
gene Inc.) which ensures the removal of protein
impurities from the final DNA solution. Comparison of
the PCR results from the two extraction methods
showed no difference, except that with NaOH extrac-
tion, the sample could not be stored for more than six
months at 4 °C. DNA from cell lines of infantile Tay–
Sachs patients (NA03461, NA03575) were obtained
from Coriell Institute for Medical Research (Camden,
NJ, USA).
Polymerase chain reaction
The primers for PCR amplification of the mutation site
were synthesized at the DNA synthesis core facility at
University of Michigan. A typical 100 µL reaction was
set up and the protocol was followed as shown in Table
1. All of the amplification reactions were performed in
a MJ Research thermocycler (M. J. Research, Water-
town, MA, USA) for 35 cycles.
Restriction enzymatic digests
The restriction enzymes and the conditions for diges-
tion are shown in Table 2. The enzymes were added
directly to the completed PCR reaction mixture along
with the respective buffers and incubated for 4 hours at
37 °C.
Purification of DNA analyses
The commercially available purification kit from Qia-
gen (Qiagen Inc., Chatsworth, CA, USA) was used to
purify the PCR products. The manufacturer’s protocols
Figure 2. (a) 8% Polyacrylamide gel electrophoresis of PCR amplified Exon 11 of Tay–Sachs gene. Lane 1: φ 3 174 marker ladder; Lane 2:
Individual A, heterozygous state; Lane 3: Individual B, normal. The ‘]’ marks two heteroduplex bands characteristic of the heterozygous state for
the 4 bp insertion mutation. (b) Gel electrophoresis results of Hae III restriction digests of Exon 11 of Tay–Sachs gene. Lane 1: 10 bp marker
ladder; Lane 2: Individual A, characterized by 43/47 bp bands; Lane 3: Individual B, normal sample (only 43 bp band).
(a) (b)
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were followed for selectively purifying DNA ≥ 100 bp.
The final eluent was dried in a SpeedVac and the DNA
sample was resuspended in 10 µL of deionized water.
1.5–2 µL of this DNA solution was used for MALDI-
MS analysis. For purification of the RFLP products
< 100 bp, the digested DNA samples were precipitated
with the addition of 0.1 volume of 3M sodium acetate
and 2 volumes of ice cold ethanol by incubating at
–75 °C overnight. This extended incubation period was
required to retrieve the smaller DNA fragments. The
precipitated DNA was allowed to form a pellet by
spinning the samples at maximum speed ( ~ 14 000
rpm) for 30 min at 4 °C (Eppendorf). The DNA pellets
were then washed with 70% ethanol and resuspended
in 10 µL of deionized water for further MALDI-MS
studies.
MALDI-MS analysis
The linear time-of-flight mass spectrometer (R. M.
Jordan Co., Grass Valley, CA, USA) used for the
MALDI analysis has been described previously.25
Briefly, 355 nm radiation obtained from a Nd:YAG
laser (Spectra Physics, Mountainview, CA, USA) was
used for desorption/ionization of the DNA samples.
The voltage settings of the ion optics used in the mass
spectrometer to detect negative ions were: –15 kV for
the repeller and –10 kV for the extractor. The detector
was a triple microchannel plate detector with a CuBe
conversion dynode capable of post acceleration up to
+ 15 kV for the MALDI-produced ions. Ion signals
were recorded on a LeCroy 9350M digital oscilloscope
and subsequently transferred to an IBM PC for data
processing. An average of 50–100 mass spectra were
recorded for each of the results presented here.
The matrices used for MALDI analysis, 3-HPA and
PA, were obtained from Aldrich Chemicals and used
without any further purification. A mixture of 3-HPA/
PA at a molar ratio of 4:1 in 36% acetonitrile and water
was used as the matrix. Nitrocellulose membrane, as an
on-probe ion-exchange membrane (Immobilon-NC
Pure, Millipore, Bedford, MA, USA) was found to be
essential in obtaining the reported mass spectra. 2 µL
(at a concentration of ~ 16 mg/ml) of nitrocellulose in
acetone was applied to the stainless steel probe tip to
produce a thin film. 1.5–2 µL of the DNA sample was
spotted on the nitrocellulose film and allowed to air dry.
Figure 3. Negative ion MALDI-MS spectra of PCR amplified Exon
11 of Tay–Sachs gene of: (a) Individual A (195/199 bp) and (b)
Individual B (195 bp). NC film substrate was used.
Figure 4. Negative ion MALDI mass spectrum of Hae III digested
Exon 11 of Tay–Sachs gene of heterozygous Individual A, charac-
terized by presence of 43 bp and 47 bp.
Figure 5. Negative ion MALDI mass spectrum of Hae III digested
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2–3 µL of HPA/PA matrix was then applied on the
dried sample.
RESULTS AND DISCUSSION
The DNA obtained from buccal cell samples of
randomly selected individuals were analyzed for two of
the three known HEXA mutations among the Ashke-
nazi Jewish population via polymerase chain amplifica-
tion followed by restriction-enzyme digestion. Both the
amplified as well as the digested products were
detected by polyacrylamide gel electrophoresis as well
as MALDI-MS analysis. The mutations in the gene
could be easily detected since each creates a character-
istic cut-site for the restriction endonuclease used.
The most common of the three mutations, a 4 bp
insertion in the Exon 11 of the Tay–Sachs gene, was
studied in two different individuals. Fig. 1 shows the
sequence of the amplified region and the restriction
sites in the Exon 11. In individual A the mutation was
identified in the heterozygous state after PCR amplifi-
cation which gave rise to two bands on the gel (195 bp
and 199 bp) (Fig. 2(a)). Individual B tested normal
based on the occurrence of only the 195 bp band (Fig.
2(a)). When the PCR product was separated by
polyacrylamide gel electrophoresis (8%) but not agar-
ose gels, the heterozygote sample always contained two
extra bands that migrated more slowly. These bands are
heteroduplexes resulting from annealing of DNA
strands from the amplified normal and mutant alleles.27
When these strands anneal, the 4 bp insertion forms a
‘bubble’ that slows the migration of the duplex in
polyacrylamide gels. Since either strand can anneal with
its counterpart in the normal amplified product, two
types of heteroduplexes are formed that migrate at
different rates.
In comparison, Fig. 3 is the negative ion MALDI
mass spectrum of PCR amplified Exon 11 of the Tay–
Sachs gene for the two cases. As always, the double
stranded samples from PCR were detected as their
respective single strands. The heteroduplexes observed
on the gel were hence absent in the final mass spectrum.
The expected amplification product of 195 bp was
clearly observed in both but could not be discerned
from the 199 bp product in Individual A (Fig. 3(a)). The
low resolution of the mass spectrometer at the high
mass end, did not allow the detection of the 4-bp
insertion as detected by gel electrophoresis (Fig.
2(a)).
The restriction enzyme, Hae III provides three
cutting sites (5'-GG/CC-3') in the amplified exon 11
sequence. The fragments generated are listed in Table 2.
In the presence of the 4-bp insertion, a 47 bp fragment
was seen in addition to the 43 bp fragment for the
heterozygote sample (Individual A) when separated by
gel electrophoresis (Fig. 2(b)). The negative ion
MALDI mass spectra of the Hae III digested Exon 11
gene from Individual A is shown in Fig. 4. All the
generated fragments from the enzymatic digests were
obtained in a single spectrum with relative ease. The
peak in the TOF mass spectrum arriving at 53 µs
corresponds to a primer (20 mer). The absence of the 12
bp fragment from digestion and the second primer is
attributed to purification procedures. An important
feature of the MALDI mass spectrum shown in Fig. 4 is
the intensity of the individual peaks which is directly
related to the concentration of the fragments generated
by the digestion. The 56 bp and 80 bp fragments are
twice as concentrated as the 43 bp and the 47 bp
fragments which are generated from a single strand of
the heterozygote duplex. This feature is also depicted in
the intensity of the bands observed on the gel (Fig.
2(b)). The negative ion MALDI mass spectrum after
enzymatically digesting DNA from Individual B, clearly
showed the absence of the 4 bp insertion mutation. Fig.
5 represents the average of 50 laser shots in the
MALDI-MS recorded from the sample of Individual
B.
The strategy for detection of the splice junction
mutation on the intron 12 of the Tay–Sachs gene was to
amplify a 120 bp fragment flanking the mutation site. In
case of the unmutated Intron 12 gene, there is only one
cutting site for the restriction enzyme, Dde I
(5'-C/T(G,A)AG-3'). Subjecting the PCR product to
enzymatic digestion with Dde I will produce fragments
of 100 bp and 20 bp. When a point mutation occurs, the
G-C base substitution at the 5' end of the intron 12
creates a new Dde I site. In this case, restriction enzyme
Figure 6. Sequence of the amplified Intron 12 region in the Tay–Sachs gene showing the splice junction mutation site available from RFLP studies
by Dde I.
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digest products include DNA fragments of 64 bp, 36 bp
and 20 bp. Fig. 6 shows the sequence of the amplified
region and the cut sites from Dde I in the Intron 12. The
fragments generated are listed in Table 2. Two individ-
uals were randomly selected for this study and both
were observed to be normal. The cell lines of an
infantile TSD sample obtained from Coriell Institute
for Medical Research on amplification followed by
restriction enzymatic digestion with Dde I, was shown
to be normal using both gel electrophoresis as well as
MALDI-MS detection. Figure 7 is the gel electro-
phoresis results obtained for this study. The MALDI-
MS of a representative PCR sample is shown in Fig. 8.
The purified 120 bp PCR product was observed at 120
µs. This spectrum was obtained as the average of 50–100
laser shots. The MALDI-MS results (Fig. 9) of the
Figure 7. 8% Poly acrylamide gel electrophoresis of Intron 12 of Tay–Sachs gene, Lane 1: φ 3 174 Marker, Lane 2: PCR product of Individual
A, Lane 3: PCR product of Individual B, Lane 4: Dde I digest of Individual A (normal), Lane 5: Dde I digest of Individual B (normal), Lane 6:
Msp I digest of pBr 322, marker.
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RFLP study indicated an unmutated gene due to the
presence of the 100 bp fragment. The absence of the
small digestion fragment of 20 bp and the primers from
the PCR process may be lost during sample
purification.
The MALDI-MS approach to study DNA samples
for screening purposes in genetically inherited dis-
orders such as the Tay–Sachs disease seems viable in
clinical labs for its speed and accuracy. Enzyme based
assay programs to prevent the disorder are designed
more to distinguish carriers from non-carriers. MALDI
based DNA testing could be a useful adjunct to the
enzyme-based assays. The most important benefit of
this technique would be the ability to identify carriers
of specific Tay–Sachs mutations, who are otherwise
indistinguishable based on enzyme assay alone. Such a
rapid and accurate technique could play a significant
role in prenatal diagnosis.
CONCLUSIONS
The results presented demonstrate the capabilities of
MALDI-MS as a clinical diagnostic in analysis of
genetic disorders amplified by PCR and RFLP. The
replacement of gel electrophoresis by the MALDI
method can speed up the time required by current
protocols followed in molecular biological labs. Use of
alternative specimens from DNA analysis such as
buccal epithelial cells instead of blood add to the cost-
effectiveness of the MALDI-MS based method. The
MALDI-MS technique has been demonstrated to be
sufficiently sensitive to detect both the PCR products as
well as their enzymatic digests with relative ease.
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